Placebo of Rituximab

DRUG2 trials

Sponsors

University Hospital, Tours, University Hospital, Rouen

Conditions

Lung Disease, InterstitialSevere Forms of Mucous Membrane Pemphigoid

Phase 3

Evaluation of Efficacy and Safety of Rituximab With Mycophenolate Mofetil in Patients With Interstitial Lung Diseases

CompletedNCT02990286

University Hospital, ToursLung Disease, Interstitial

Start: 2017-01-20End: 2020-02-17Updated: 2025-12-30

Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid

Active, not recruitingNCT03295383

University Hospital, RouenSevere Forms of Mucous Membrane Pemphigoid

Start: 2019-07-11End: 2027-03-01Updated: 2026-06-10

Related Papers

Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial

European Respiratory Journal2023-05-25111 citations

Evaluation of efficacy and safety of rituximab in combination with mycophenolate mofetil in patients with nonspecific interstitial pneumonia non-responding to a first-line immunosuppressive treatment (EVER-ILD): A double-blind placebo-controlled randomized trial.

2020-05-239 citations